Business
Oxford Biomedica Signs Agreement with Arcellx
Oxford Biomedica Signs Agreement with Arcellx.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3584V\n Oxford Biomedica PLC\n 13 December 2021\n \n \n \n \n \n \n \n \n \n \n \n Oxford Biomedica \n \n \n Signs Licence & Supply Agreement with Arcellx, Inc. for LentiVector® Platform for CAR-T Therapeutics\n \n \n \n \n \n \n Oxford, UK - 13 December 2021: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or \"the Group\"), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (\"LSA\") with Arcellx, Inc. (\"Arcellx\"), a Gaithersburg MD.-based biotechnology company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The LSA grants Arcellx a non-exclusive licence to Oxford Biomedica's LentiVector® platform for its application in select Arcellx CAR-T programmes and puts in place a three-year Clinical Supply Agreement.\n Under the terms of the LSA, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials. Additionally, the agreement allows for payments to the Group for the manufacture and supply of lentiviral vectors for commercial use.\n \n This partnership with a leader in the CAR-T field builds on the longstanding partnerships with Novartis and Bristol Myers Squibb, as well as the more recently announced partnership with Beam Therapeutics.\n \n \n \n John Dawson, Chief Executive Officer of Oxford Biomedica, said:\n \n \n \n \"Arcellx is one of the leading next-generation CAR-T developers deploying a wide range of innovative technologies to bring innovative CAR-T products into development. We are proud to be working with a leader in the field of CAR-T that shares our vision of delivering cell and gene therapies to save lives. This is yet another valuable opportunity for our LentiVector® platform to support innovative product development of CAR-T products further highlighting Oxford Biomedica's position as a partner of choice.\"\n \n \n \n \n Rami Elghandour, Chairman and CEO of Arcellx said\n \n \n : \n \n \n \"We look forward to leveraging Oxford Biomedica's renowned LentiVector\n \n \n \n ®\n \n \n \n platform technology, and their industry-leading development and GMP manufacturing expertise in the clinical and commercial development of...